The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Beta‐Amyloid, Phospho‐Tau and Alpha‐Synuclein Deposits Similar to Those in the Brain Are Not Identified in the Eyes of Alzheimer's and Parkinson's Disease Patients
Open accessAbstract
A lzheimer's disease (AD) and P arkinson's disease (PD) are the two most common neurodegenerative disorders, and are characterized by deposition of specific proteins in the brain. If similar abnormal protein deposits are present in the eye, it would facilitate noninvasive diagnosis and monitoring of disease progression. We therefore evaluated expression of proteins associated with AD and PD pathology in postmortem eyes and brains in a case‐control study. Eyes from 11 cases of AD, 6 cases of PD or PD with dementia, and 6 age‐matched controls were retrieved from the autopsy archives of T he J ohns H opkins H ospital. Immunostains for β‐amyloid, phospho‐tau and α‐synuclein and C ongo red stains were performed in the same laboratory in both brains and eyes. No amyloid deposits or abnormal tau accumulations were detected in the lens, retina or other structures in the eyes of AD patients. Eyes also lacked definite L ewy bodies or L ewy neurites in either PD or AD cases. Patchy cytoplasmic α‐synuclein positivity was seen in the retina of AD, PD and control cases, but did not correlate with the presence or extent of L ewy body pathology in the brain. Abnormal protein aggregations characteristic of AD and PD are thus not commonly present in the retinas or lens of affected patients when assayed using the same protocols as in the brain. This suggests that β‐amyloid, phospho‐tau and α‐synuclein either do not deposit in the eye in a manner analogous to brain, or are present at lower levels or in different forms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 1×
“The AD cases included nine cases of definite AD with a CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) plaque score C and Braak tangle score IV-VI/VI, and two cases of probable AD with a CERAD score B and Braak score II-IV/VI (male : female = 3:7; median age: 82 years; range 61–92 years) (4, 22).”
MethodAlzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Köpke, E., Tung, Y. C., Shaikh, S., Alonso, A. C., Iqbal, K., & Grundke-Iqbal, I. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80536-5 · Cited by 779
Koronyo-Hamaoui, M., Koronyo, Y., Ljubimov, A. V., Miller, C. A., Ko, M. K., Black, K. L., Schwartz, M., & Farkas, D. L. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.06.020 · Cited by 672
Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer's disease
Alexandrov, P. N., Pogue, A., Bhattacharjee, S., & Lukiw, W. J. (2011) · Neuroreport · doi:10.1097/wnr.0b013e3283497334 · Cited by 128
Ocular manifestations of Alzheimer's disease in animal models
Parnell, M., Guo, L., Abdi, M., & Cordeiro, M. F. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/786494 · Cited by 56 · cited 1×
“Animal models in which AD-associated proteins are overexpressed provide additional support for the concept that the disease can affect the eye (1, 2, 5, 25, 27, 30), although in such models it is often unclear if the levels or sites of abnormal protein expression faithfully recapitulate those seen in human disease.”
Background
Cited by
Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease
Koronyo, Y., Biggs, D., Barron, E., Boyer, D. S., Pearlman, J. A., Au, W. J., Kile, S. J., Blanco, A., Fuchs, D.-T., Ashfaq, A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93621 · Cited by 510
Spectral-Domain OCT Measurements in Alzheimer’s Disease
Chan, V. T. T., Sun, Z., Tang, S., Chen, L. J., Wong, A., Tham, C. C., Wong, T. Y., Chen, C., Ikram, M. K., Whitson, H. E., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.08.009 · Cited by 360
Hadoux, X., Hui, F., Lim, J. K. H., Masters, C. L., Pébay, A., Chevalier, S., Ha, J., Loi, S., Fowler, C. J., Rowe, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12242-1 · Cited by 304
Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer’s Disease Brain
DeVos, S. L., Corjuc, B. T., Oakley, D. H., Nobuhara, C. K., Bannon, R. N., Chase, A., Commins, C., Gonzalez, J. A., Dooley, P. M., Frosch, M. P., et al. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00267 · Cited by 285
“…nervous system in that it is not only completely devoid of neuronal cell bodies, but the axonal projections in the ON derive from the retinal ganglion cells, a neuronal cell type that does not develop NFTs (Blanks et al., 1989; Ho et al., 2014), and synapses onto the lateral geniculate nucleus.”
BackgroundOcular indicators of Alzheimer’s: exploring disease in the retina
Hart, N. J., Koronyo, Y., Black, K. L., & Koronyo-Hamaoui, M. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1613-6 · Cited by 261
Metadata
- Authors
- Ho, C., Troncoso, J. C., Knox, D., Stark, W., & Eberhart, C. G.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2013-06-28
- Volume
- 24
- Issue
- 1
- Pages
- 25-32
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- OpenAlex
- W1933624512
- Cited by
- 159
- References
- 8
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.